Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia
- PMID: 2149053
- DOI: 10.1111/j.1365-2141.1990.tb07937.x
Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia
Abstract
In a prospective randomized study, 100 episodes of fever (greater than 38 degrees C) and granulocytopenia (less than 1000/microliters) in cancer patients were empirically treated with ceftazidime (2 g every 8 h) plus teicoplanin (400 mg every 8 h on day 1; 400 mg every day thereafter) or ceftazidime (2 g every 8 h) plus amikacin (500 mg every 8 h). Bacteraemia, clinically documented infection and possible infection were documented in seven, 11 and 19 patients treated with ceftazidime plus teicoplanin and in 11, four and 17 patients treated with ceftazidime plus amikacin. Overall, the response rate was similar in the two groups of patients as was the need for treatment modifications and the rate of death. For documented Gram-positive bacteraemia, the response rate was 2/5 patients treated with ceftazidime plus teicoplanin and 2/7 with ceftazidime plus amikacin; for documented Gram-negative bacteraemia, the response rate was 1/2 and 3/4 patients respectively. No breakthrough bacteraemia was observed. Tolerance was excellent, although renal toxicity (elevation of serum creatinine) was observed in three patients treated with ceftazidime plus teicoplanin and in none allocated to ceftazidime plus amikacin.
Similar articles
-
Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients.Antimicrob Agents Chemother. 1987 Jul;31(7):1126-9. doi: 10.1128/AAC.31.7.1126. Antimicrob Agents Chemother. 1987. PMID: 2959198 Free PMC article. Clinical Trial.
-
Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.Oncol Rep. 1998 Sep-Oct;5(5):1205-9. doi: 10.3892/or.5.5.1205. Oncol Rep. 1998. PMID: 9683836 Clinical Trial.
-
Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.Br J Haematol. 1990 Dec;76 Suppl 2:45-8. doi: 10.1111/j.1365-2141.1990.tb07936.x. Br J Haematol. 1990. PMID: 2149052
-
Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients.Br J Haematol. 1990 Dec;76 Suppl 2:19-23. doi: 10.1111/j.1365-2141.1990.tb07930.x. Br J Haematol. 1990. PMID: 2149046 Clinical Trial.
-
Empiric treatment of infection during granulocytopenia: a comprehensive approach.Infection. 1989 Mar-Apr;17(2):59-64. doi: 10.1007/BF01646877. Infection. 1989. PMID: 2654018 Review. No abstract available.
Cited by
-
Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1994 May;47(5):823-54. doi: 10.2165/00003495-199447050-00008. Drugs. 1994. PMID: 7520860 Review.
-
Once-daily pefloxacin + teicoplanin vs netilmicin + teicoplanin in empirical therapy for fever and neutropenia.Drugs. 1995;49 Suppl 2:483-5. doi: 10.2165/00003495-199500492-00143. Drugs. 1995. PMID: 8549409 Clinical Trial. No abstract available.
-
Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients--a double-blind, randomised, prospective, controlled trial.Support Care Cancer. 2005 Dec;13(12):993-1000. doi: 10.1007/s00520-005-0812-9. Epub 2005 Apr 16. Support Care Cancer. 2005. PMID: 15834740 Clinical Trial.
-
A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours.Infection. 1998 Nov-Dec;26(6):389-95. doi: 10.1007/BF02770842. Infection. 1998. PMID: 9861566 Review.
-
Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.Drugs. 1990 Sep;40(3):449-86. doi: 10.2165/00003495-199040030-00007. Drugs. 1990. PMID: 2146108 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical